GU Cast

When Fred Saad (Urologist, University of Montreal, Montreal) and Andrew Weickhardt (Medical Oncologist, Austin Health, Melbourne) popped into our studio recently we decided to pick their brains on a few hot topics in mHSPC - we called it the ABC of mHSPC! Fred was in Melbourne to visit Peter Mac and do some educational talks and we loved welcoming him back on GU Cast. A is for ARPIs - who/when/which? B is for treatment Break - can we use an intermittent approach to ADT/ARPI doublets without yet having trials in the ARPI era to guide us? C is for Chemo - surely there is almost no role for docetaxel chemo in the ARPI era?? Or so asks Declan, well known triplet therapy sceptic! Do Fred and Andrew agree??!A great overview of hot topics in mHSCP! Thanks to Fred and Andrew! With your usual hosts Declan Murphy and Renu Eapen.Even better on our YouTube channel 

A big welcome back to EAU Guideline gurus, Dr Derya Tilki (Martini-Klinik, Hamburg, Germany), and Dr Gianluca Giannarini (Santa Maria della Misericordia University Hospital, Udine, Italy), for an overview of the major headlines from this year's EAU Guideline update. Derya is Deputy Chair of the EAU Prostate Cancer Guideline Committee and has picked out four areas to discuss. These are: 1. New stratification for favourable and unfavourable prostate cancer2. PSMA PET/CT now recommended for unfavourable intermediate-risk cancer3. No change to PLND recommendations due to lack of benefit in MSKCC RCT update4. Importance of multidisciplinary approach for mHSPCSo tune in so you can pretend you have read the full 250 page 2025 Guideline!! Your usual co-hosts are Professor Declan Murphy and Dr Renu Eapen.Even better on our Youtube channelLinks:Updated 2025 EAU Prostate Cancer Guideline 

For serious PSMA theranostics enthusiasts!!! We bring you the ninth of our collaborative PSMA webinars over the past five years, in collaboration with our team at ProsTIC and at the Prostate Cancer Foundation in the US. A truly outstanding faculty presenting today including Misha Beltran, Marty Pomper, Ed Kwan and Louise Emmett.Co-hosted by Declan Murphy and Michael Hofman with a welcome from Howard Soule and Andrea Miyahira. Declan and Michael are joined in studio by Louise Kostos who helps field the many questions from the huge global audience who joined us live. Much better appreciated on our YouTube channel where you can see all the presentations 

What is the da Vinci Single Port (SP) robot and is it any good? Is it easy to transition from the multiport robot to a single port robot? What about Retzius-sparing prostatectomy using the SP robot? GU Cast hosts Declan Murphy and Renu Eapen learn the answers to these questions and more when we visit top prostate cancer surgeons Dr Declan Cahill and Prof Chris Eden at London Bridge Hospital, to see the UK's only SP robot in action. The SP robot has been approved in the US for a few years, and now approved in Europe and Australia, so we hope to have it available for our patients very soon. Plus we see how they use the Neurosafe intra-operative margin assessment technique at London Bridge Hospital. This one definitely best enjoyed on our YouTube channel This is a Themed Episode supported by our Partners, Device Technologies.

Like very many countries around the world our friends in China are big fans of the EAU Guidelines, and are always tuned in when the updated Prostate Cancer Guidelines is released every year. So as part of our China Themed Episode Series, supported by our Gold Partners Bayer China, we are discussing some key updates to this year's Guideline with our China Editor Dr Yao Zhu (Shanghai) along with Dr Junlong Zhuang (Nanjing).Even better on our Youtube channel 

A bit of a break from the usual GU Oncology routine today folks! Declan was back at Guy's Hospital recently doing a talk and heard a remarkable story told by one of the Urology Fellows, Dr Joachim Jimie. A quite spectacular mid-air crisis, and some great life lessons in there also.Declan could not resist the opportunity to grab Jimie and tell the tale again for GU Cast. Enjoy!!!Even better on our YouTube channel 

180 episodes later and Declan and Renu have cracked out the champagne in the GU Cast studio! Tune in for this quick pod with some reminiscing and some thank you's, especially to you our global audience!

Radiation cystitis! Now this can be a really challenging condition for urologists, and especially for patients, to manage and to live with. And we frequently struggle to get good results. It is often years and years after radiation to the pelvis when patients return with problems like bleeding, pain, incontinence, fistula etc, which can have everything from minor, to ruinous effects on quality of life. And although these are radiation oncology patients, it is the urologist (and sometimes other surgeons) who have to manage these unfortunate side-effects of radiation.Today we travel to London to chat with two Urologists at Guy's Hospital who have set up a dedicated clinic to manage Radiation Cystitis patients from across the UK. Dr Ramesh Thurairaja and Dr Yasmin Abu Ghanem, explain why they set up this service, and share with us their strategy for assessing and managing radiation cystitis. This episode is full of useful advice for anyone out there managing radiation cystitis, and hopefully might inspire more people to set up similar clinics to look after these unfortunate patients. Even better on our Youtube channelLinks:Guy's Hospital Radiation Cystitis Clinic Pelvic Radiation Disease Best Practice Pathway

More great highlights from the recent EAU Annual Meeting in Madrid. Declan and Renu chat with Christian Gratzke, Sima Pore]ten, Yinjie Zhu, Rod Dunn, and have a most entertaining "pit lane walk" with Ben Challacombe around the various robots in the exhibition area. GU Cast Conference Highlights are supported by our Conference Highlights Partner, Bayer China.Even better on our YouTube channel

Declan and Renu bring you some great highlights from the recent EAU Annual Meeting in Madrid. Hear from Laurie Klotz and Adam Kinnaird about the OPTIMUM RCT, Sarah Psutka and Laura Bukavina discuss their bladder cancer highlights, Riccardo Campi talks biomarkers, changes in practice and other highlights, and Rod van den Bergh and Eoin Dinneen debate the finer points of the NEUROSAFE Proof RCT. GU Cast Conference Highlights are supported by our Conference Highlights Partner, Bayer China. Even better on our YouTube channel Links: OPTIMUM paper in JAMA Our Neurosafe podcast 

Really big prostate cancer news today with the release of very interesting results from the Neurosafe Proof trial at the EAU Annual Meeting in Madrid. Also simultaneously published in Lancet Oncology so this is a big deal!! In summary, this multi centre randomised trial from the UK demonstrates that men undergoing the Neurosafe technique (intra-operative assessment of surgical margins), had higher rates of nerve sparing surgery and this in turn led to improvements of recover of sexual function. We were delighted to have a detailed discussion on this with key members of the University College London team who led this trial - Prof Greg Shaw, Dr Eoin Dinneen, and Dr Ricardo Almeida-Magana.This is a Themed Podcast supported by our Gold Partner, MundipharmaEven better on our YouTube channelLinks:Full paper in Lancet Oncology Funders: National Institute for Health ResearchJP Poulton Charitable FoundationRosetree TrustOrchid

We are delighted to drop this pod just as the landmark TRANSLATE trial reads out at the EAU Annual Meeting in Madrid, with a simultaneous publication in Lancet Oncology. This is the world's largest trial of transrectal vs transperineal (TP) prostate biopsy, and reports that TP biopsy has superior cancer detection ability. Is this the end of the road for TRUS biopsy. Hosts Declan Murphy and Renu Eapen are delighted to welcome first and senior authors, Prof Richard Bryant and Dr Alastair Lamb of the University of Oxford to have a detailed discussion about TRANSLATE and what this means for prostate biopsy. `Even better on our YouTube channel Links:Lancet Oncology paperFunders: 

Declan Murphy is in the GU Cast studio in Shanghai with GU Cast China Editor, Prof Yao Zhu. We sit down with Prof Hao Zeng (West China Hospital) and Dr Ye Yan to discuss their experiences and perspectives on advancements in diagnostics like MRI and PSMA PET, the increasing use of Chinese-developed robotic surgery platforms, and the ongoing debate surrounding pelvic lymph node dissection. They also address the application of systemic therapies for metastatic disease, considering the unique characteristics of the Chinese patient population and the potential for dose adjustments. Today's pod also highlights the growing importance of precision oncology, including genomic testing for mutations to guide treatment decisions, while acknowledging the challenges and future directions in this area.This is a Themed Podcast supported by our Gold Partner, Bayer China. Even better on our YouTube channel https://youtu.be/xlOuS4swcuc

This week we had the great pleasure of attending the Annual Scientific Meeting of the Urological Society of Australia and New Zealand (USANZ), which took place in the beautiful city of Perth, far out on the West Coast of Australia. Not just that, but we spent a wonderful afternoon on one of Australia's top tourist attractions, Rottnest Island. Tune in for plenty of quokka action! Plus, of course we bring you some great conference highlights, chatting with international guests, including Laura Bukavina, Alberto Breda, Samir Taneja, plus Australian guests, Nathan Lawrentschuk, Michael Chamberlain, and Scientific Convener Trenton Barrett.GU Cast conference highlights are brought to you by our Conference Highlights partner, Bayer China.Even better on our YouTube channel (check out Rottnest Island and the Quokkas)!!

A fantastic episode for urologists, radiation oncologists, and anyone interested in localised prostate cancer. Biochemical recurrence (BCR) is unfortunately all too common after surgery or radiation for prostate cancer, and today we talk with someone who has been working in BCR for more than 20 years. Dr Steve Freedland, Urologist at Cedars-Sinai in Los Angeles, popped into the GU Cast studio to talk about the landmark series from Johns-Hopkins Medical Institute (links below) which still today remains our best guide to the natural history of BCR after radical prostatectomy. And the key message that PSA doubling time is our most important tool to risk stratify patients reminds true today. And Steve of course is the lead investigator of the EMBARK trial, published in NEJM in 2023, which has led to a new standard of care for men experiencing high-risk BCR after surgery or radiotherapy. EMBARK has clearly shown us that the use of enzaluamide, either on its own, or with androgen deprivation therapy, reduces the risk of metastases when compared with ADT alone. We dive deep into EMBARK with Steve.This is a Themed Podcast supported by our Gold Partners, Astellas. Astellas also supported Steve to be in Australia this week for the USANZ ASM in Perth, and visits to Melbourne and Sydney. Your hosts are Professor Declan Murphy and Dr Renu Eapen. Even better on our Youtube channelLinks:Freedland et al JAMA 2005 EMBARK paper in NEJM

Two great international visitors recently led to two great sets of podcast chats!! Dr Kim Chi (Vancouver), and Dr Carmen Mir (Valencia) were in Melbourne to speak at the PROSPECT Meeting (see links below). We grabbed Kim along with Prof Arun Azad (Peter MacCallum Cancer Centre, Melbourne), and Dr Louise Kostos (also Peter Mac), to overlook some hot topics in mHSPC. And then a cracking chat with Carmen along with two Europeans doing Urology Fellowship training in Melbourne  - Dr Christa Babst (Peter MacCallum Cancer Centre/Switzerland), and Dr Marta Alves (Royal Melbourne Hospital/Barcelona). Carmen had also done a Fellowship in Melbourne at Austin Health so could give some great perspectives. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also supported the recent PROSPECT meeting. Even better on our YouTube channelLinks:PROSPECT podcast Part 1PROSPECT Podcast Part 2

A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!! A 45% reduction in the risk of death in favour of the combination. Plus excellent quality of life for those receiving the combo. We are joined by Louise and co-author A/Prof Andrew Weickhardt (Austin Health, Melbourne), to discuss this exciting data from the ENZA-P trial, and what it means for the future of not just mCRPC, but also for similar combinations in mHSPC.ENZA-P is an investigator-initiated Phase II trial led by ANZUP in partnership with the Prostate Cancer Research Alliance, a join initiative between the Australian Government and Movember. Your co-hosts as ever are Professor Declan Murphy and Dr Renu Eapen. This is a Themed podcast supported by our Gold Partners, Astellas, and our Silver Partners, Novartis. Even better on our YouTube channelLinks:Lancet Oncology paperANZUP 

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs  on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer. We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business. Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne.This is a Themed Podcast supported by our Silver Partners, Novartis. Even better on our YouTube channelLinks:Michael's paper in the Journal of Nuclear Medicine:"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"

Dr Toni Choueiri, Chief of GU Oncology at Dana-barber Cancer Institute (Boston, USA) returns to GU Cast with members of his team at Dana Farber Cancer Institute to discuss our favourite lists of top GU Oncology papers for 2024. Toni has posted these now legendary lists at the end of each year on Twitter/X since the start of Covid, and they have become essential reading for anyone wanting a superb overview of top trials. Each tweet contains a top line summary of each trial and key images such as K-M curves, plus links to the original papers. A huge amount of work and a great resource. Today we are joined by Toni along with Dr Marc Eid and Dr Emre Yekeduz who helped compile this year's lists. We hear about the process behind it all, and we run through their Top 10 Bladder and Renal Cancer papers, and their Top 5 Prostate Cancer papers. The team also post their Top 10 Translational papers and Their Top 10 non-GU Oncology papers. Well done again to Toni, Marc, Emre and team! Links to the tweets below. Even better on our YouTube channelLinks:Top 10 Bladder and Renal Cancer Papers Top 5 Prostate Cancer Papers 

Part 2 of our GU Cast Conference Highlights from Shanghai including discussions with Dr Stephen Freedland (Los Angeles), Dr Liang Liang (Shaanxi), Dr Andrea Necchi (Milano), Dr Xiaojie Bian (Shanghai), and Dr Hongkai Wang (Shanghai).  Declan Murphy travelled to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities. In Part 1 we spoke to Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger, to overview the latest stories in GU Oncology. Special thanks to our Conference Highlights Partner, Bayer China, who set up an amazing GU Cast studio for us in Shanghai. Thanks to Hexun and all the local Bayer team in China.  Also available as an audio podcast - just search GU Cast wherever you get your podcasts

Declan Murphy travels to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities, and this year Declan joins International Faculty including Dr Stephen Freedland (Los Angeles), Dr Karim Fizazi (Paris), Dr Axel Merseburger (Lubeck). and Dr Andrea Necchi (Milano) to overview the latest stories in GU Oncology. Top Chinese experts from across the country also join and the meeting includes some landmark consensus statements from multidisciplinary panels.Today we post Part 1 of our GU Cast Conference Highlights from Shanghai including discussions with Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger. Special thanks to our Conference Highlights Partner, Bayer China, who set up an amazing GU Cast studio for us in Shanghai. Thanks to Hexun and all the local Bayer team in China. Even better on our YouTube channel 

Our final episode of the year! And we end with a very seasonal celebration of single-port surgery and the Boxing Day Test with Australia playing India in one of the world's most famous cricket matches. We coaxed Dr Mihir Desai (University of Southern California, Los Angeles) and A/Prof Daniel Moon (Peter Mac, Melbourne) out of the Melbourne Cricket Ground and into our nearby studio at the close of play on Day 2 to talk all things single-port surgery (and cricket). Cricket-mad Mihir flew in from LA to tick off his bucket list ambition of attending a Boxing Day Test. We reminisce about the early days of single-port laparoscopy and talk about what robotic surgery does (and does not) bring to single-port surgery. Plus we remember the day that Indy Gill met Shane Warne at the MCG ten years ago while attending a meeting here! Two legends of their games. And to end season 5 of GU Cast, your hosts Declan Murphy and Renu Eapen thank our amazing Partners for supporting our ever expanding pool of content from GU Cast. Even better on our YouTube channelLinks:BJUi Blog about when Indy met Warnie 

Have you ever found the choice of agents in metastatic kidney cancer just a bit perplexing??! Well then this is the podcast for you! To celebrate a fantastic review paper recently published in European Urology, we chat with first author Dr Regina Barragan-Carillo (City of Hope, California), and second senior author Dr Tian Zhang (UT South-Western, Texas). The title of the paper is "First and Second-line Treatments in Metastatic Renal Cell Carcinoma", and it's about the best paper we have read on this topic, with a proper who's who in renal cancer contributing. Plus completely up to date with a literature review up to October 2024. Co-hosts Declan Murphy and Renu Eapen really enjoyed this one! This is a Themed Podcast supported by our Bronze Partner, Ipsen Pharmaceuticals. Even better on our YouTube channel Links:European Urology paper (paywall) 

Legendary British cyclist Sir Chris Hoy (48) recently shocked the world by announcing that he has progressive metastatic prostate cancer. His specialists have given him a 2-4 year life expectancy. The dreadful news that no prostate cancer patient wants to hear. Today, hosts Prof Declan Murphy and Dr Renu Eapen welcome their good mates A/Prof Ben Challacombe (Guy's Hospital, London), and A/Prof Daniel Moon (Peter MacCallum Cancer Centre, Melbourne) to the GU Cast studio, and patient advocate Andrei Norris who joins on Zoom to discuss the huge publicity this has generated, and the importance of family history in assessing men's risk of prostate cancer. This is a Themed Podcast supported by our Silver Partners, Bayer Pharmaceuticals. Even better on our YouTube channel

Part 2 Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months.Part 2 today features controversies in PLND, the somewhat notorious ARPI switch control arm beloved of mCRPC trials, and teh importnt topic of de-escalation in advanced prostate cancer. Part 1 recently in your feeds included PSMA conundrums and triplet vs doublet therapy.Even better on our YouTube channelThis is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. Special thanks to David Chen for help with videography

What are we to make of this large RCT of extended vs standard pelvic lymph node dissection (PLND) for prostate cancer?? Despite it not meeting its primary endpoint of improving biochemical recurrence, the authors now report in European Urology that it does reduce the incidence of distant metastases 10 years later! Go figure! We chat with Dr Karim Touijer (MSKCC) and try to figure it out. We ask about data dredging, p-hacking and statistical shenanigans, and how adding two minutes and two extra lymph nodes to a PLND could possibly lead to reduced metastases. Plus guest comments from Dr John Yaxley (Brisbane). What do you think??!! Will this change practice?? Will this change guidelines? Tune in and share your thoughts!Even better on our YouTube channelLinks:Paper in European Urology Previous GU Cast with Karim discussing earlier paper (Feb 2022) 

Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months. Part 1 today features PSMA conundrums and triplet vs doublet therapy. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. Special thanks to David Chen for help with videography

Everything you need to know about treatment intensification in mHSPC!! Doublet vs Triplet. Who should have radiotherapy? PSMA PET/CT conundrums, e-escalation, case discussions and more. Featuring GU Cast Hosts Declan Murphy and Renu Eapen, Medical Oncologist Ben Tran, Nuclear Medicine Physician Louise Emmett, and Radiation Oncologist Amy Hayden. Plus lots of interaction from our live audience around Australia.Watch the full webinar including presentations on our YouTube channelThis GU Cast Live Event was an interactive educational webinar supported by our Gold Partners, Mundipharma.Learning objectives: 1. Provide an overview of the landscape of mHSPC today, with a particular focus on intensification of therapy2. Provide an overview of the role of novel and conventional imaging in diagnosis of mHSPC, both synchronous and metachronous3. To better understand options for intensification of systemic therapy in mHSPC4. To better understand the role of radiotherapy in mHSPC

In the third of our special episodes focussing on GU Oncology in China, we are delighted to welcome back our GU Cast China Editor, Professor Yao Zhu, who has selected three huge prostate cancer highlights from the recent #ESMO24 meeting in Barcelona.  We are joined by Professor Shouzhen Chen (Qilu Hospital, Shandong University), and Professor Zhenhua Liu (Sichuan University, West China Hospital) to discuss PEACE-3, ARANOTE, and UpFront PSMA, and in particular to consider what these data mean to health care professionals and patients in China. This is a Themed Podcast as part of our Gold Partnership with Bayer Pharmaceuticals in China. We are very grateful to Bayer China for helping us promote GU Cast in China and supporting these Themed Episodes.Even better on our YouTube channelYou can also catch our recent full GU Cast Conference Highlights from #ESMO24 here 

Today we celebrate one of our favourite clinical trials - ENZAMET! It is 10 years since ENZAMET opened and beyond its pivotal data establishing that adding enzalutamide to ADT improves survival for mHSPC patients, it continues to produce a very strong stream of high-quality findings that affect our practice today. ENZAMET also straddled an epochal era which included the advent of doectaxel upfront in mHSPC, and the introduction of PSMA PET/CT. Today we were very happy to speak to two of the principal architects of ENZAMET; Professor Ian Davis, Chair of the ANZUP co-operative trials group, and Professor Chris Sweeney. Director of the South Australian ImmunoGENomics Cancer Institute, who told us the extraordinary story of how this trial came about, the challenges and evolutions of its rollout, and the strong tail end of translational and other research which it continues to produce. It is a great example of how investigator initiated trials run by nimble and ambitious cooperative trial groups like ANZUP can do things a little differently.This is a Themed Podcast supported by our Gold Partners, Astellas. Een better on our YouTube channelLinks:ANZUP Previous podcast from #ANZUP24 Annual Scientific MeetingENZAMET 2019 paper NEJM ENZAMET 2023 paper Lancet Oncology

Ask anyone which big oncology meeting gave us the best GU oncology highlights this year and the answer is easy! ESMO24 in Barcelona! Jammed full of key papers and so many highlights, Declan and Renu bring you a great overview in this GU Cast Conference Highlights from ESMO24. Listen to discussions with investigators and key opinion leaders, interviews with delegates, a fun speed-walk through the prostate cancer poster session, and a fun morning at the OncoAlert 5K.GU Cast Conference Highlights ares supported by our Conference Highlights Partner, Bayer China. Even better on our YouTube channel

Penis Project is one of our favourite podcasts (and certainly popular with our patients), so we were delighted to welcome Host and Sexologist, Melissa Hadley-Barrett to join us for a chat. What is the Penis Project? Who is it for? (anyone with a penis, anyone who knows someone with a penis, or anyone who would like to have a penis apparently)! A cracking chat and we highly recommend subscribing. Just search Penis Project or browse the links belowEven better on our YouTube channelWebsites:https://melissahadleybarrett.com   Men's health onlyhttps://rshealth.com.au/  All gendersSPECIAL OFFER - use the code MHB10 at the checkout on all the programs (penile rehab and erectile dysfunction and peyronies) or in the shop to get a 10% discount. Facebook:https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/https://www.facebook.com/profile.php?id=100085146627814 Instagram:https://www.instagram.com/melissahadleybarrett/https://www.instagram.com/restorativehealth.clinic/TikTok: @melissahadleybarrettYouTube: Melissa Hadley BarrettLinkedin:https://www.linkedin.com/in/melissa-hadley-barrett/TEDXhttps://www.youtube.com/watch?v=IjHj1YTmLoA

The world's longest running live robotic surgery meeting took place in Bordeaux last week and Declan and Renu were there to bring you all the highlights! The 21st Meeting of the EAU Robotic Urology Section (ERUS) was their biggest ever with more than 1000 delegates watching more than 40 live surgeries from the world's top robotic surgeons. And this year includes some quite spectacular telesurgery with surgeons in Bordeaux and patients 8000km away in Beijing!! Renu takes a few new robots for a test drive, and we catch up with some of the biggest names in the business. This is a Themed Episode supported by our Silver Partners,  Device Technologies Australia, distributors of the da Vinci Surgical System across Australia, New Zealand and South-East AsiaEven better on our YouTube channel

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.  We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA. This is a Themed Podcast supported by our Silver Partners, Novartis.Even better on our YouTube channelFull paper in Lancet Oncology here 

More than 500 salvage radical prostatectomies!!! Yep it would be fair enough to describe Dr Paul Cathcart as being "experienced" in the most challenging scenario  we face as prostate cancer surgeons. Surgery for cancer recurrence in the prostate following radiotherapy or various forms of ablative therapy is never easy, and can all too often lead to issues with healing and quality of life recovery due to the impact of prior failed treatments, so we are always keen to see how we can improve outcomes.  Paul dropped into the GU Cast studio when back in Melbourne this week, a little over ten years on from his Fellowship training here. He is a Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, where his main area of expertise is indeed salvage robotic radical prostatectomy. Paul shares his perspectives and tips and tricks for performing this procedure to try and give patients the best possible outcome, and also explains why he prefers the da Vinci Surgical System over the new robot kids on the block. This is a Themed Podcast supported by our Silver Partners, Device Technologies, distributors of the da Vinci Surgical System. Even better on our YouTube channel

Testis cancer! We don't talk enough about this on GU Cast. But we are making up for it today with a cracking overview of three hot topics in testis cancer a couple of  world-leading testis cancer experts. We are joined by Rob Hamilton (Urologist, Princess Margaret Cancer Centre, Toronto), and Ben Tran (Medical Oncologist, Peter Mac, Melbourne) to discuss changes in surveillance for stage 1 seminoma, changes in the management of stage 2 seminoma (including robotic RPLND), and miRNA as a really useful biomarker. A really lively discussion on three really topical areas in testis cancers. Even better on our YouTube channel We recorded this one at the ANUP Annual Scientific Meeting in July 2024. You can find a full GU Cast covering the rest of the ANZUP24 highlights here 

As if any of us need an excuse to go to beautiful Bali! Well the Urological Association of Asia (UAA) Annual Meeting takes place there from 5-8th September 2024. Renu caught up with Dr Agus Rizal Hamid recently to hear what the UAA have in store for us!www.uaa2024.com

How often do you check PSA and testosterone in your patients on androgen deprivation therapy? Declan caught up with friend of the podcast Professor Axel Merseburger at a conference recently to chat about thsi under-appreciated topic. Don't get too distracted by fancy scans and genomic testing; but do make sure you know a bit about why it matters to get testosterone (and PSA) as low as possible. This is a Themed Podcast supported by our Gold Partners, Mundipharma. Even better on our YouTube channel

Today we dedicate our podcast to the memory of our colleague, Dr Brian Kelly (40), who passed away unexpectedly this week. We are devastated to lose Brian, who was a Consultant Urologist at Peter Mac and Eastern Health here in Melbourne, and one of our closest friends in the world. Here we replay the Memorial Session which we conducted at Peter Mac this week. It features some great memories of Brian from contributors across the world; all of us shocked to lose one of the most special people in our urological community. Our heartfelt condolences to Brian's mother Margaret, siblings Finnian, Sean and Ruth, and his son Tadhg. Vale Brian we will miss you always xYouTube for full video 

We were very happy to have world-famous kidney cancer guru Dr Rana McKay in Australia this week to do some educational events and to visit us at Peter Mac. So of course we also invited her to the GU Cast studio to pick her brains on all things kidney cancer, along with Dr Lewis Au, GU Medical Oncologist at Peter Mac. We asked them to cover three hot topics: 1. Adjuvant immunotherapy following surgery for kidney cancer2. First line management of metastatic kidney cancer - how do we choose best options for individual patients?  3. Future-gazing in renal cancer, including a focus on belzutifan.Even better on our YouTube channel Rana's visit to Australia was supported by our friends at MSD, Silver Partners of GU Cast. Links: Previous GU Cast on Keynote-564Renu's new paper in Nature Reviews Urology! (mentioned in the intro) 

Renu and Declan escape winter in Melbourne to enjoy a few days of sunshine and science at the #ANZUP24 Annual Scientific Meeting on the Gold Coast. ANZUP is our fantastic GU Oncology co-operative trials group here in Australia and New Zealand and have an outstanding record in running clinical trials and supporting research and education in GU Oncology. Plus this is their 14th Annual Scientific Meeting with some outstanding National and International guests. We catch up with Paul Nguyen, Elena Castro, Ravi Kanesvaran, Fiona McLean, Cristiane Bergerot and Co-Convenor Matt Roberts to bring you some great highlights of this year's meeting.GU Cast Conference Highlights are supported by our Gold Partners, Bayer China. Even better on our YouTube channelLinks:ANZUP 

To celebrate the Paris 2024 Olympics, we bring you this special Olympics-themed episode of GU Cast - our very own Prostate Cancer Olympics! Yes we We are joined in the GU Cast studio by Dr Elena Castro, GU Medical Oncologist at Hospital 12 de Octubre in Madrid, who happened to be passing through Melbourne. And by our own A/Professor Arun Azad, GU Medical Oncologist at Peter MacCallum Cancer Centre, and one of our GU Cast Clinical Advisors. We have three events and some great medal contenders, but who will win Gold??!! Tune in for some great discussion and debate, and some surprises and controversies along the way. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals. Even better on our Youtube channel 

In the second of our special episodes focussing on GU Oncology in China, we are delighted to welcome back our GU Cast China Editor. Professor Yao Zhu, who has put together this cracking epsiode focussing on radical prostatectomy in China. We are joined by Professor Ming Liu (Beijing Hospital, Beijing) and Professor Jiahua Pan (Ren Ji Hospital, Shanghai) to discuss everything from current practices of pelvic lymph node dissection up to tantalising details of the new surgical robots which are in clinical use in China. This is a Themed Podcast as part of our Gold Partnership with Bayer Pharmaceuticals in China. We are very grateful to Bayer China for helping us promote GU Cast in China and supporting these Themed Episodes. Even better on our YouTube channel

There are patient advocates and there are patient advocates, and then there is Howard Wolinksy! We chat with the inimitable Howard, medical journalist and very long-time active surveillance patient, about his varied interests in low-risk prostate cancer and prostate cancer diagnostics. He runs a great substack called The Active Surveillor with a regular newsletter which we devour every week! l His  current interests are in the abolition of transrectal prostate biopsy and the campaign to re-name grade group 1/Gleason 6 cancer as a non-cancer. We chat about all this and more, including that unforgettable appearance he made at the ASCO GU Plenary session! Also available on our YouTube channelSubscribe to the Active Surveillor here 

Part 2 of our Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this episode we chat with Elena Castro, Nick James, Anthony Joshua, Bertrand Tombal, Silke Gillessen, Aurelius Tomlin, Yüksel Ürün, Gill Morgan, and a gang of nuclear medicine phyicians including Michael Hofman, Louise Emmett, Tom Hope, Stefano Fanti, and Ken Herrmann. GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast. Even better on our YouTube channel

Pelvic lymph node dissection down-graded. Systematic prostate biopsies no longer recommended. More clarity around PSMA PET/CT for staging. Surgery no longer recommended for cN1 prostate cancer. Yep the recent updates to the EAU Prostate Cancer Guidelines had a lot of important changes for the global urology community to digest. So we invited EAU Prostate Cancer Guideline Vice-Chair Derya Tilki, and Guideline Board Member Gianluca Giannarini, along with Elio Mazzone to join us for a deep dive into these major changes.  All you need to know!Even better on our YouTube channel 

The first of two Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this epsiode we chat with Silke Gillessen, Derya Tilki, Jochen Walz, Neha Vapiwala, Dingwei Ye, and the lucky trainees who won a GU Cast Travel Award to attend this year's APCCC. GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast. Even better on our YouTube channel 

Didn't get to ASCO this year?? Us neither!! But not to worry, we checked in with Dr Marty Schoen who did, and brings us all the key highlights! Marty is a GU Medical Oncologist at the St Louis Veterans Affairs Medical Centre and the University of St Louis, Missouri. He runs through a smattering of stuff that caught his eye at ASCO this year. Thanks Marty! Also on our YouTube channel

For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers might remember we discussed this on GU Cast back in August 2021 when the disease-free survival endpoint was published in NEJM, and it would be fair to say we were cautious and kept saying "we need to wait for the overall survival data". Well here we are! Patients who received pembro for one year had a 38% reduced risk of death. Big news! We are joined again by Dr Alex Kutikov, Urologist at Fox Chase Cancer Centre, who joined us on the original podcast. We are also joined by his colleague GU Medical Oncologist, Dr Matt Zibelman, who has a lot of experience in this area having been an investigator on the IMmotion 010 study. Unfortunately lead author Dr Toni Choueiri could not join us this time but he gets plenty of mentions!This is a Themed Podcast supported by our Silver Partners, MSD, manufacturers of pembrolizomab, through an educational grant. MSD had no input into the content of this podcast. Even better on our YouTube channelLinks:Full NEJM paper Previous GU Cast on K-564

Should we remove bladder cancers piece-meal by chopping them into little pieces, or should we try and remove en bloc with a margin around the base?? This very nice randomised controlled trial from our friends in Hong Kong demonstrates that the recurrence rate is significantly lower if we use the all-too-rarely used en bloc technique. Dr Jeremy Teoh from the Chinese University Hong Kong joins us to discuss his paper just published in European Urology. Check out the YouTube version for a video of the technique.Also available as an audio only podcast wherever you get your podcasts Full paper here 

Today we have Dr Alicia Morgans, GU Medical Oncologist and Director of Survivorship at Dana Farber Cancer Institute, in the GU Cast studio for a chat. We wanted to ask Alicia to look forward and identify three big challenges  we will face in metastatic prostate cancer over the next 5-10 years. What did we come up with??!! Tune in to find out!!Even better on our YouTube channel